GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Relay Therapeutics
Relay Therapeutics is a biotech company using an innovative approach to drug discovery based on studying protein movement. Its stock price is a venture bet on the success of its scientific platform. The chart reflects volatility associated with news from the lab.
Share prices of companies in the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to discover highly selective targeted cancer drugs. We've categorized it as a "Targeted Oncology" company. The chart below shows how the market values innovative approaches to cancer drug development.
Broad Market Index - GURU.Markets
Relay Therapeutics uses advanced computational methods to discover highly selective, targeted cancer therapies. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
RLAY - Daily change in the company's share price Relay Therapeutics
Shares of Relay Therapeutics, an oncology company, are highly volatile. Change_co measures the market reaction to clinical trial data from its drugs. This metric is an essential component in building valuation models for companies at the forefront of targeted therapy on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Relay Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with RLAY's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Relay is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Relay stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Relay Therapeutics
Relay is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are teetering on the edge of anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Relay Therapeutics, Inc. is a biotechnology company using advanced computational methods to discover new cancer drugs. Its innovative platform is its key advantage. The chart shows how the market views its technological approach and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Relay Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Relay Therapeutics
Summit, a REIT that owns a portfolio of economy hotels, displays monthly fluctuations in the graph, reflecting tourism and business activity, which impacts occupancy and pricing at its hotels, located primarily in urban and suburban areas.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to discover highly targeted cancer drugs. This biotech segment, located at the intersection of AI and medicine, is attracting enormous interest. This chart shows how much investors believed in the potential of computational biology to create a new generation of drugs, and how this belief has evolved over time.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Relay Therapeutics uses cutting-edge technologies to develop targeted cancer therapies. It's a science-driven biotech company. Its stock moves based on progress in research and clinical trials, betting that its new approach to drug development will prove successful.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Relay Therapeutics
Relay Therapeutics uses cutting-edge technologies to develop targeted cancer therapies. Weekly stock performance is highly volatile, driven by news of progress in its research and early-stage clinical trial data.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using cutting-edge technologies. Comparing its weekly performance with the broader biotech sector only highlights its uniqueness. The chart shows how news about its scientific platform drives share price movements independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Relay, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
RLAY - Market capitalization of the company Relay Therapeutics
Relay Therapeutics' market cap tells the story of a cutting-edge approach to drug discovery based on studying protein movement. This biotech's stock price reflects investors' faith in its innovative platform. Its volatility reflects the market's reaction to early clinical trial data, which may confirm the power of this new method.
RLAY - Share of the company's market capitalization Relay Therapeutics within the market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using advanced computational methods to study protein dynamics to develop highly targeted cancer therapies. Its market share reflects the potential of its innovative platform. The chart below demonstrates the market's confidence in its ability to "hack" the protein machinery of disease.
Market capitalization of the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to understand protein movement to create more effective cancer drugs. The chart below shows the total market capitalization of the oncology sector, demonstrating how innovative approaches to drug development can change the treatment paradigm for complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows a new era in drug discovery. Relay Therapeutics uses supercomputers to study protein movement to create more precise cancer drugs. Its capitalization is a bet that computational chemistry will revolutionize pharmaceuticals. This is a visualization of "smart" drug discovery.
Book value capitalization of the company, segment and market as a whole
RLAY - Book value capitalization of the company Relay Therapeutics
Relay Therapeutics' book value is derived from its Dynamo scientific platform for discovering drugs that target protein dynamics and its financial reserves. This capital is built on a breakthrough scientific concept. The chart shows how the biotech company accumulates and spends funds to test its innovative hypothesis in clinical trials.
RLAY - Share of the company's book capitalization Relay Therapeutics within the market segment - Oncology targeted therapy
Relay Therapeutics uses cutting-edge technologies to understand protein movement to create new cancer drugs. Its assets include powerful computing clusters and laboratories. The graph will show that the company's value lies in its unique scientific platform, not its manufacturing capacity.
Market segment balance sheet capitalization - Oncology targeted therapy
Developing targeted therapies, like Relay Therapeutics', is a science-intensive but relatively "easy" business at the R&D stage. Its value lies in the drug discovery platform. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Relay Therapeutics' book value is derived from its cutting-edge laboratories, equipped with powerful computers for modeling protein dynamics. Its assets reflect its unique technology platform for developing precision cancer drugs. The chart illustrates the physical foundation of this innovative approach to pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Relay Therapeutics
Relay Therapeutics, a biotech company with an innovative approach to drug development, is valued by the market at multiples of its lab value. Investors are paying for the potential of its platform, which studies protein movement to create more precisely targeted drugs.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using advanced computational methods to discover cancer drugs. Its high valuation on this chart reflects investors' faith in its innovative platform, which can speed up and reduce the cost of drug development.
Market to book capitalization ratio for the market as a whole
Relay Therapeutics is a biotech company using advanced computational methods to understand protein movement and develop new drugs based on this understanding. Its valuation reflects its unique scientific platform. This metric demonstrates how the market values innovative approaches to drug development that can speed up and reduce the cost of drug discovery.
Debts of the company, segment and market as a whole
RLAY - Company debts Relay Therapeutics
Relay Therapeutics, a biotech company developing targeted cancer therapies, funds its cutting-edge but expensive research with raised capital. This chart reflects the enormous investment required to work at the cutting edge of science, where every step requires significant financial resources.
Market segment debts - Oncology targeted therapy
Relay Therapeutics is a biotech company using advanced computational methods to understand protein dynamics to create more effective targeted cancer therapies. This innovative approach requires significant investment in R&D. The chart shows how the company funds its scientific platform and advances its developments through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Relay Therapeutics
Relay Therapeutics uses advanced computational methods to discover highly specific, targeted cancer drugs. This innovative approach to drug development requires massive investments in technology and lengthy clinical trials. This chart shows how the company uses debt to fund its science- and capital-intensive research.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Relay Therapeutics is a biotech company using an innovative approach to drug discovery by studying protein movement. This cutting-edge science, however, requires significant investment. This chart shows how the company finances its unique research, comparing its debt structure to the broader picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Relay Therapeutics uses cutting-edge technologies to develop targeted cancer drugs. Biopharmaceutical innovation requires significant, long-term investment. How much does the company rely on debt to finance its breakthrough research? This chart of total market debt provides context for assessing its financial strategy and risks.
P/E of the company, segment and market as a whole
P/E - Relay Therapeutics
Relay Therapeutics is a biotech company using advanced computational methods to discover highly selective, targeted cancer drugs. This chart shows how investors value its innovative platform. The high valuation reflects the belief that its approach will lead to the development of more effective drugs.
P/E of the market segment - Oncology targeted therapy
Relay Therapeutics is a clinical-stage biotechnology company that uses a cutting-edge computational platform to develop highly selective, targeted cancer therapies. This chart shows the average valuation for the sector, helping to understand the market premium placed on Relay's innovative approach to drug discovery.
P/E of the market as a whole
Relay Therapeutics is a biotech company using advanced computational methods to discover new cancer drugs. Its approach promises to accelerate development. Does the company's valuation reflect the general interest in biotech, or is it a unique bet on its innovative platform, which could be a game-changer for pharmaceuticals?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Relay Therapeutics
Relay Therapeutics uses advanced computational methods to study protein dynamics to create more effective targeted cancer drugs. This chart reflects investors' faith in the company's innovative approach. Future profits depend entirely on the success of its platform in developing breakthrough drugs and bringing them to market.
%20P%2FE%20Relay%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Relay-Therapeutics&v=1772571301432 "Chart of the company's future (projected) P/E Relay Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to study protein dynamics to create more effective targeted cancer therapies. This innovative approach to drug development is reflected in the chart below, which shows forecasts for the oncology sector. This helps compare market confidence in Relay's breakthrough platform with expectations from other biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772571301467 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Relay Therapeutics is a biotech company using an innovative approach to drug discovery by studying protein movement. This is fundamental science, and the company's valuation reflects its belief in its platform. This chart shows the market's willingness to invest in science-intensive platform companies with long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772571301605 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Relay Therapeutics
Relay Therapeutics uses advanced computational methods to discover new targeted cancer drugs. The company is at the forefront of science, and its financial results reflect the losses from intensive research. This chart illustrates how investments in breakthrough technologies can lead to the creation of a new generation of drugs.
Profit of companies in the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to understand protein movement to create more effective targeted cancer drugs. This chart, reflecting the pharmaceutical sector's profitability, highlights the investment climate. Their innovative approach requires significant investment, and positive industry momentum is helping attract capital for this breakthrough research.
Overall market profit
Relay Therapeutics uses advanced computational methods to discover new cancer drugs. The company operates at the intersection of technology and biology. Raising capital for such innovative approaches depends on the overall investment climate. Growing corporate profits, as shown in this chart, increases investor appetite for risky but potentially breakthrough biotech companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Relay Therapeutics
Relay Therapeutics uses advanced computational methods to understand protein dynamics to create more effective targeted cancer therapies. This graph represents analyst expectations for the success of their innovative platform and progress in clinical trials, paving the way for a new era in drug development.
%20profit%20of%20the%20company%20Relay%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Relay-Therapeutics&v=1772571302198 "Graph of future (projected) profit of the company Relay Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using advanced computational methods to discover highly selective, targeted cancer drugs. Its value lies in the potential of its innovative platform. This chart for the oncology sector demonstrates the overall market belief that new technologies can lead to more effective and safer drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772571302375 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Relay Therapeutics uses cutting-edge technologies to develop targeted cancer drugs. The company's success depends on scientific breakthroughs. However, the overall profit forecast, reflected in the chart, influences investor willingness to fund capital-intensive biotech research with long development cycles.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772571302389 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Relay Therapeutics
Relay Therapeutics is a biotech company using advanced computational methods to discover targeted cancer drugs. Despite the lack of revenue, this chart is crucial. It shows how investors view its innovative platform and future sales potential, betting on a breakthrough in precision medicine.
P/S market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to discover highly selective, targeted cancer therapies. The company's valuation is based on the potential of its innovative Dynamo platform. This chart reflects the average valuation in the sector, demonstrating how much investors believe Relay's technological approach will lead to the development of effective drugs.
P/S of the market as a whole
Relay Therapeutics is a biotech company using advanced computational methods to understand protein movement to create more effective cancer drugs. This chart, which reflects real-world business revenue estimates, clearly demonstrates the premium investors are willing to pay for innovative scientific approaches that could lead to the creation of fundamentally new classes of drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Relay Therapeutics
Relay Therapeutics is a biotech company using advanced computational methods to discover precision cancer drugs. Their approach promises to accelerate development. This chart shows how investors view the potential of their innovative platform to create a full portfolio of effective drugs in the future, not just a single product.
%20P%2FS%20Relay%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Relay-Therapeutics&v=1772571302765 "The graph of the company's future (projected) P/S Relay Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods and experimental approaches to understand protein dynamics and develop drugs for targeted cancer therapy. This chart reflects average future revenue expectations in the biotech sector. It provides insight into the market's appreciation of Relay Therapeutics' innovative drug discovery platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772571303042 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Relay Therapeutics uses advanced computational methods and structural biology to develop highly targeted cancer therapies. The chart below shows how the market generally views its revenue growth prospects. Relay's innovative approach to drug discovery fuels hopes for a breakthrough in oncology, a key driver of overall investor optimism in the biotech space.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772571303166 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Relay Therapeutics
This chart illustrates the revenue of Relay Therapeutics, a biopharmaceutical company that uses advanced computational methods to develop highly targeted cancer drugs. Its clinical-stage revenue is generated through collaboration fees with major pharmaceutical companies, reflecting the progress of its scientific platform rather than drug sales.
Sales of companies in the market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using an innovative platform to understand protein dynamics to create highly selective, targeted cancer therapies. This chart illustrates the growing oncology market. Relay's unique scientific approach could lead to the development of a new class of drugs capable of overcoming resistance to existing therapies.
Overall market sales
Relay Therapeutics is a biotech company developing targeted therapies for cancer treatment. Its market capitalization is based on the potential of its scientific platform. The overall economic environment, shown in this chart, influences investor willingness to fund long-term, capital-intensive oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Relay Therapeutics
Relay Therapeutics uses advanced computational methods to develop targeted cancer drugs. Future revenue depends on the success of its innovative R&D platform. The chart reflects analyst expectations for the commercialization of drugs developed using artificial intelligence.
%20sales%20of%20the%20company%20Relay%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Relay-Therapeutics&v=1772571303649 "Schedule of future (projected) sales of the company Relay Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Relay Therapeutics is a biotechnology company that uses advanced computational methods to understand protein dynamics and create highly targeted cancer therapies. This chart shows the outlook for the oncology market, where Relay's innovative approach could lead to the development of a new class of drugs for difficult-to-treat cancers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772571303842 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Relay Therapeutics uses advanced computational methods to discover new cancer drugs. The company is at the intersection of biotechnology and artificial intelligence. This chart reflects the overall investment climate, and Relay Therapeutics' progress demonstrates how new technologies are accelerating the drug development process, a key driver for the entire pharmaceutical industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772571303919 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Relay Therapeutics
Relay Therapeutics uses advanced computational methods to discover targeted cancer drugs. The company is in clinical trials, which requires significant investment. This chart reflects its net loss—the cost of a groundbreaking approach to drug development that could revolutionize the fight against cancer.
Market segment marginality - Oncology targeted therapy
Relay Therapeutics is a biotech company using an innovative platform to discover highly selective, targeted cancer therapies. Profitability is a long-term goal. This chart reflects investment in research and development. Investors evaluate it to understand the potential of their unique approach to creating next-generation oncology drugs.
Market marginality as a whole
Relay Therapeutics is a biotech company using advanced computational methods to study protein movement to create more effective cancer drugs. Their approach is a new way of thinking about drug development. This overall profitability curve isn't important to them. Their future is determined by scientific progress and the ability of their platform to create breakthrough drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Relay Therapeutics
Relay Therapeutics is a biotech company using cutting-edge technologies to develop targeted cancer therapies. Its growing team consists of scientists and drug development specialists. The growth in this chart reflects the progress of its innovative platform and the advancement of candidates into clinical trials.
Share of the company's employees Relay Therapeutics within the market segment - Oncology targeted therapy
Relay Therapeutics uses cutting-edge technologies to understand protein dynamics to create more effective targeted cancer drugs. This chart shows the share of scientific talent the company attracts in this innovative field of biotechnology. The growth in this indicator indicates the expansion of its research platform and progress in creating next-generation drugs.
Number of employees in the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods to study protein dynamics and develop new targeted cancer drugs. This chart shows employment trends at the intersection of biotechnology and IT. The growth in computational biology and chemistry specialists reflects a new era in drug development, where artificial intelligence helps create more precise and effective molecules.
Number of employees in the market as a whole
Relay Therapeutics is a biotechnology company using advanced computational methods to understand protein movement and develop highly precise cancer drugs. This innovative approach opens new horizons in medicine. This figure demonstrates how breakthroughs at the intersection of biotechnology and IT are creating unique jobs for the next generation of scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Relay Therapeutics (RLAY)
Relay Therapeutics is a biotech company using an innovative drug discovery platform (protein flow analysis). This chart represents the pure intellectual capital valuation. The market values the potential of its unique scientific platform, not its staff. The chart shows the high future value investors are placing on this technology per scientist.
%20of%20the%20company%20Relay%20Therapeutics%20(RLAY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Relay-Therapeutics-RLAY&v=1772571304503 "Chart of market capitalization per employee (in thousands of dollars) of the company Relay Therapeutics (RLAY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using an innovative approach to drug discovery based on the study of protein motility. Its value is driven by its unique scientific platform. This chart shows the high market valuation of its cutting-edge technologies and intellectual property per scientist.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772571304552 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Relay Therapeutics is a biotech company that uses an innovative approach to studying protein movement to develop new cancer drugs. The chart reflects the valuation of its cutting-edge scientific platform. The company's entire value is derived from its intellectual capital. This metric demonstrates the value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772571304626 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Relay Therapeutics (RLAY)
Relay Therapeutics is a biotech company using advanced computational and experimental methods (studying protein movement) to discover new cancer drugs. This R&D is at the forefront of science. This chart shows the cost of these technologies: the enormous investment required for each scientist working on targeted drug development.
%20Chart%20Relay%20Therapeutics%20(RLAY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Relay-Therapeutics-RLAY&v=1772571304648 "Company Profit Per Employee (in thousands of dollars) Chart Relay Therapeutics (RLAY)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Relay Therapeutics (RLAY) is a biotech company using advanced computational methods (protein dynamics) to develop cancer drugs. This is deep clinical-stage science. This metric (loss per employee) reflects the high cost of R&D, which combines wet labs and supercomputers.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772571304677 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Relay Therapeutics is a biotech company using advanced computational methods (the Dynamo platform) to discover new oncology drugs. This is "techbio" R&D. The company is profitless. This chart shows the capital burn rate: the operating loss per team of scientists and engineers working on this expensive platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772571304689 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Relay Therapeutics (RLAY)
Relay Therapeutics uses advanced computational methods to discover targeted cancer drugs. This chart reflects the progress of monetizing its innovative platform. During the research phase, revenue is generated through collaborations with major pharmaceutical companies, and the growth in revenue per employee demonstrates the value and promise of their scientific approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Relay-Therapeutics-RLAY&v=1772571304695 "Sales chart per company employee Relay Therapeutics (RLAY)")
Sales per employee in the market segment - Oncology targeted therapy
Relay Therapeutics uses advanced computational methods (protein dynamics) to discover new cancer drugs. This graph shows how productive their team of scientists and programmers is. It measures revenue (from partnerships) per employee, which is an indicator of the effectiveness of their R&D platform in the targeted therapy segment.
Sales per employee for the market as a whole
Relay Therapeutics (RLAY) is a biotech company using advanced computational methods (protein dynamics) to discover new targeted cancer drugs. The company is in the clinical stage. This chart illustrates the R&D landscape: the company has no commercial revenue, and its entire staff of scientists and programmers is working on developing future assets.
Short shares by company, segment and market as a whole
Shares shorted by company Relay Therapeutics (RLAY)
Relay Therapeutics is a company using advanced computational methods (protein dynamics) to develop targeted cancer therapies. This approach is high-tech, but speculative. This chart shows bearish bets. Investors are skeptical that this complex platform can truly lead to effective drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Relay-Therapeutics-RLAY&v=1772571304965 "Short Shares Chart for the Company Relay Therapeutics (RLAY)")
Shares shorted by market segment - Oncology targeted therapy
Relay Therapeutics is a biotech company using the advanced computational platform Dynamo to discover new cancer drugs. This indicator reflects skepticism. The "shorts" here are betting that their hyped-up scientific platform will fail to produce real drugs that pass clinical trials.
Shares shorted by the overall market
Relay Therapeutics uses cutting-edge technologies to develop targeted cancer drugs. This is fundamental science, requiring hundreds of millions of dollars. When fear mounts on this chart, "long money" becomes short. Investors are unwilling to wait 5-10 years for a drug's approval, preferring to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Relay Therapeutics (RLAY)
Relay Therapeutics (RLAY) is a biotech company using the Dynamo computational platform to understand protein movements. They are developing precision oncology drugs. This chart measures hype. It shows "overheated" (above 70) due to positive trial data or "oversold" (below 30) amid high cash burn and a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Relay-Therapeutics-RLAY&v=1772571305155 "RSI 14 indicator chart for the company's stock Relay Therapeutics (RLAY)")
RSI 14 Market Segment - Oncology targeted therapy
Relay (RLAY) is a biotech company using an AI platform (Dynamo) to develop precision targeted cancer therapies. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is RLAY's volatility a reaction to its trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Relay Therapeutics (RLAY) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RLAY (Relay Therapeutics)
Relay Therapeutics (RLAY) is a biotech company using computational methods (Dynamo platform) to discover new targeted cancer therapies. This chart represents analyst consensus. Their price targets are based on their technology platform and early data on their oncology drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RLAY-Relay-Therapeutics&v=1772571305216 "A chart showing analyst consensus forecasts for the expected stock price. RLAY (Relay Therapeutics)")
The difference between the consensus estimate and the actual stock price RLAY (Relay Therapeutics)
Relay Therapeutics (RLAY) is a biotech company using the Dynamo computational platform to model protein motion to create more precise cancer drugs. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their scientific approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RLAY-Relay-Therapeutics&v=1772571305252 "A chart showing the difference between the consensus forecast and the actual stock price. RLAY (Relay Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Relay Therapeutics (RLAY) is a "TechBio" company that uses the advanced Dynamo computing platform to "capture" protein movements and create more precise cancer drugs. This chart shows general expectations for the targeted oncology sector, reflecting whether experts believe in breakthrough R&D methods based on supercomputers.
Analysts' consensus forecast for the overall market share price
Relay Therapeutics (RLAY) is a biopharmaceutical company that uses supercomputers to create movies. They simulate protein movements to create more precise targeted cancer treatments. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but capital-intensive R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Relay Therapeutics
Relay Therapeutics is a next-generation biotech company. They use supercomputers (the Dynamo platform) to map protein movements to create more precise cancer drugs. This chart is a pure R&D bet. It likely reflects the market's faith in their high-tech Dynamo platform and their early clinical data in oncology.
AKIMA Market Segment Index - Oncology targeted therapy
Relay Therapeutics (RLAY) is a clinical-stage biotech and a pioneer in protein dynamics. The company uses its unique R&D platform (Dynamo) to develop targeted cancer therapies. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough R&D platform (RLAY) differentiate it from the average pharma company?
The AKIM Index for the overall market
Relay Therapeutics is a biotech company that uses computer modeling of protein motion to create precision cancer drugs. It's a crossroads of physics and biology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this tech-focused R&D platform stacks up against overall economic trends and risk appetite.
